Tempest Therapeutics, Inc.: Executive or director change
Tempest Therapeutics entered into a research services agreement with Factor Bioscience, appointed a new director to regain Nasdaq compliance, and appointed a new Chief Financial Officer.
Neutral newsWhat happened
- Tempest entered into a Master Services Agreement and initial work order for in vivo CAR-T therapies with related party Factor Bioscience Inc.
The full interpretation is in the app
Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.
Read the full interpretation